Vivos Inc. (RDGL)

Market Cap	24.71M -39.4%
Revenue (ttm)	99.10K +91.5%
Net Income	-3.60M
EPS	-0.01
Shares Out	494.21M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	85,718
Open	0.0450
Previous Close	0.0484
Day's Range	0.0440 - 0.0504
52-Week Range	0.0400 - 0.1244
Beta	-0.71
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About Vivos

Vivos Inc., a radiation oncology medical device company, engages in the development of yttrium-90-based precision radionuclide therapy devices for the treatment of non-resectable tumors in the United States. The company develops RadioGel, which is an injectable particle-gel for Precision Radionuclide Therapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. It is also developing PLGA-g-PEG polymers; PrecisionGel, a hydrogel polymer platform for delivering active pharmaceutica...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1994
• Employees: 1
• Stock Exchange: OTCMKTS
• Ticker Symbol: RDGL

Financial Performance

In 2025, Vivos's revenue was $68,379, an increase of 144.25% compared to the previous year's $27,995. Losses were -$3.07 million, 5.35% more than in 2024.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 1, 2026

Data Sources Report a data error